Page last updated: 2024-11-13
aspergillide b
Description
aspergillide B: cytotoxic 14-membered macrolide from marine-derived fungus Aspergillus ostianus strain 01F313; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
aspergillide B : A macrolide that is 4,15-dioxabicyclo[9.3.1]pentadec-9-en-3-one substituted by a hydroxy group at position 14 and a methyl group at position 5 (the 1S,5S,9E,11R,14S stereoisomer). It is isolated from the marine-derived fungus Aspergillus ostianus and exhibits cytotoxic activity against mouse lymphocytic leukemia cells (L1210). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (5)
| Synonym |
|---|
| aspergillide b |
| CHEBI:65451 , |
| (1s,5s,9e,11r,14s)-14-hydroxy-5-methyl-4,15-dioxabicyclo[9.3.1]pentadec-9-en-3-one |
| CHEMBL2407404 |
| Q27133895 |
Roles (2)
| Role | Description |
|---|
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| Aspergillus metabolite | Any fungal metabolite produced during a metabolic reaction in the mould, Aspergillus. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
| Class | Description |
|---|
| bridged compound | A polycyclic compound in which two rings have two or more atoms in common. |
| cyclic ether | Any ether in which the oxygen atom forms part of a ring. |
| macrolide | A macrocyclic lactone with a ring of twelve or more members derived from a polyketide. |
| secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID762592 | Antiproliferative activtiy against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay | 2013 | Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
| Medicinal chemistry of dihydropyran-based medium ring macrolides related to aspergillides: selective inhibition of PI3Kα. |
| AID762593 | Antiproliferative activtiy against human HL60 cells assessed as growth inhibition after 48 hrs by MTT assay | 2013 | Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
| Medicinal chemistry of dihydropyran-based medium ring macrolides related to aspergillides: selective inhibition of PI3Kα. |
| AID762591 | Cytotoxicity against human FR2 cells after 48 hrs by MTT assay | 2013 | Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
| Medicinal chemistry of dihydropyran-based medium ring macrolides related to aspergillides: selective inhibition of PI3Kα. |
| AID762590 | Antiproliferative activtiy against human A375 cells assessed as growth inhibition after 48 hrs by MTT assay | 2013 | Journal of medicinal chemistry, Aug-08, Volume: 56, Issue:15
| Medicinal chemistry of dihydropyran-based medium ring macrolides related to aspergillides: selective inhibition of PI3Kα. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.31 (24.57) | | Research Supply Index | 2.20 (2.92) | | Research Growth Index | 4.51 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |